New Phase II data from China demonstrate that relma-cel CAR-T therapy delivers high response rates and durable survival in heavily pretreated relapsed/refractory mantle cell lymphoma patients.
Get a concise overview of the 2025 Chinese expert consensus on T-cell immunotherapy for aggressive B-cell lymphoma, including key updates, treatment highlights, and clinical insights.
In this video, we share the courageous journey of a patient diagnosed with mantle cell lymphoma (MCL), a rare and aggressive type of non-Hodgkin lymphoma. After undergoing multiple rounds of
A 57 yo high risk MCL achieved CR for two years after treatment with Carveyta, a innovative CAR T-cell therapy recently received
The China NMPA has approved new indication, mantel cell lymphoma (MCL), to Carteyva (Relma-cel), this is the third indication approved for this innovative CAR T-cell therapy.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.